Michael Harrington - Elanco Animal Independent Director
ELAN Stock | USD 16.17 0.28 1.76% |
Director
Mr. Michael J. Harrington is an Independent Director of the Company. Mr. Harrington has served as a director on Elancos board since September 2018. Mr. Harrington has served as the Senior Vice President and General Counsel for Lilly since January 2013. Prior to 2013, Mr. Harrington served in various legal roles for Lilly, including Vice President and Deputy General Counsel of Global Pharmaceutical Operations from 2010 to 2012 and Vice President and General Counsel, Corporationrationrate from 2004 to 2010. Mr. Harringtons experience described above, including his knowledge of Elanco and the animal health industry and his business and management experience, provides him with the qualifications and skills to serve as a director on Elancos board. since 2018.
Age | 58 |
Tenure | 6 years |
Address | 2500 Innovation Way, Greenfield, IN, United States, 46140 |
Phone | 877 352 6261 |
Web | https://www.elanco.com |
Michael Harrington Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Harrington against Elanco Animal stock is an integral part of due diligence when investing in Elanco Animal. Michael Harrington insider activity provides valuable insight into whether Elanco Animal is net buyers or sellers over its current business cycle. Note, Elanco Animal insiders must abide by specific rules, including filing SEC forms every time they buy or sell Elanco Animal'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Harrington over two weeks ago Acquisition by Michael Harrington of 3100 shares of Elanco Animal at 16.2883 subject to Rule 16b-3 |
Elanco Animal Management Efficiency
The company has return on total asset (ROA) of 0.0139 % which means that it generated a profit of $0.0139 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1822) %, meaning that it created substantial loss on money invested by shareholders. Elanco Animal's management efficiency ratios could be used to measure how well Elanco Animal manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of March 2024, Return On Capital Employed is likely to grow to 0.03, though Return On Assets are likely to grow to (0.08). As of the 28th of March 2024, Asset Turnover is likely to grow to 0.33, while Total Assets are likely to drop about 13.6 B.Similar Executives
Showing other executives | DIRECTOR Age | ||
Willard Dere | Seres Therapeutics | 64 | |
Werner Cautreels | Seres Therapeutics | N/A | |
Carina Olofsson | 23Andme Holding Co | 42 | |
Ettore Artioli | 23Andme Holding Co | N/A | |
Tadataka Yamada | Agilent Technologies | 74 | |
Staffan Gavel | 23Andme Holding Co | 67 | |
Bruce Kovner | Madrigal Pharmaceuticals | 69 | |
Stephen Connelly | Equillium | 42 | |
Dow Wilson | Agilent Technologies | 61 | |
Paul Clark | Agilent Technologies | 72 | |
Lorence Kim | Seres Therapeutics | 43 | |
Kurt Graves | Seres Therapeutics | 50 | |
David Berry | Seres Therapeutics | 37 | |
Salvatore Falco | 23Andme Holding Co | 46 | |
Anthony Tjan | Equillium | N/A | |
Martha Demski | Equillium | 65 | |
Sue Rataj | Agilent Technologies | 63 | |
Americo Romano | 23Andme Holding Co | 58 | |
Hans Bishop | Agilent Technologies | 56 | |
Dennis Ausiello | Seres Therapeutics | 72 | |
Heidi Fields | Agilent Technologies | 60 |
Management Performance
Return On Equity | -0.18 | ||||
Return On Asset | 0.0139 |
Elanco Animal Health Leadership Team
Elected by the shareholders, the Elanco Animal's board of directors comprises two types of representatives: Elanco Animal inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Elanco. The board's role is to monitor Elanco Animal's management team and ensure that shareholders' interests are well served. Elanco Animal's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Elanco Animal's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jose Simas, Executive Vice President U.S. Farm Animal Business | ||
Joshua Smiley, Independent Director | ||
Chris Keeley, Senior Officer | ||
Carl McMillian, Independent Director | ||
Katy Grissom, Head Relations | ||
Ellen Brabander, Executive Vice President - Innovation and Regulatory Affairs | ||
Sarena Lin, Executive Vice President, Global Marketing, Corporate Strategy and Transformation | ||
Paul Herendeen, Independent Director | ||
Racquel Mason, Executive Vice President and Chief Marketing Officer, Elanco Animal Health | ||
Rajeev Modi, Executive Vice President - U.S. Pet Health and Global Digital Transformation | ||
Jeffrey Simmons, President, Chief Executive Officer, Director | ||
Denise ScotsKnight, Independent Director | ||
David Kinard, Executive Vice President, Human Resources, Corporate Affairs and Administration | ||
David Urbanek, Executive Vice President - Manufacturing, Quality | ||
Aaron Schacht, Executive Vice President, Innovation, Regulatory and Business Development | ||
R Hoover, Independent Chairman of the Board | ||
Larbi Lier, Senior Asia | ||
Kirk McDonald, Independent Director | ||
James Meer, Senior Vice President, Chief Accounting Officer | ||
Art Garcia, Independent Director | ||
Shiv ONeill, General President | ||
Joyce Lee, Executive Vice President and President U.S. Pet Health and Commercial Operations | ||
David Hoover, Chairman of the Board | ||
Kapila Anand, Independent Director | ||
Michael Harrington, Independent Director | ||
Todd Young, Chief Financial Officer, Executive Vice President | ||
David Ricks, Independent Director | ||
Marcela Kirberger, Executive Vice President General Counsel, Company Secretary | ||
Scott Ferguson, Independent Director | ||
Shawn McKee, Sr Animal | ||
Deborah Kochevar, Independent Director | ||
Lawrence Kurzius, Independent Director | ||
Ramiro Cabral, Executive Vice President - Elanco International and Global Customer Value | ||
Aarti Shah, Independent Director | ||
Dirk Ehle, Executive Vice President and President Elanco Europe | ||
William Doyle, Independent Director | ||
John Bilbrey, Independent Director | ||
MichaelBryant Hicks, Executive Vice President General Counsel, Secretary |
Elanco Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Elanco Animal a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.18 | ||||
Return On Asset | 0.0139 | ||||
Profit Margin | (0.28) % | ||||
Operating Margin | 0.02 % | ||||
Current Valuation | 13.26 B | ||||
Shares Outstanding | 492.97 M | ||||
Shares Owned By Insiders | 0.65 % | ||||
Shares Owned By Institutions | 99.23 % | ||||
Number Of Shares Shorted | 13.69 M | ||||
Price To Earning | 241.75 X |
Elanco Animal Investors Sentiment
The influence of Elanco Animal's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Elanco. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Elanco Animal's public news can be used to forecast risks associated with an investment in Elanco. The trend in average sentiment can be used to explain how an investor holding Elanco can time the market purely based on public headlines and social activities around Elanco Animal Health. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Elanco Animal's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Elanco Animal's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Elanco Animal's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Elanco Animal.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Elanco Animal in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Elanco Animal's short interest history, or implied volatility extrapolated from Elanco Animal options trading.
Pair Trading with Elanco Animal
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Elanco Animal position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Elanco Animal will appreciate offsetting losses from the drop in the long position's value.Moving together with Elanco Stock
0.83 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
Moving against Elanco Stock
0.7 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
0.64 | MEIP | MEI Pharma Financial Report 9th of May 2024 | PairCorr |
0.64 | CALT | Calliditas Therapeutics Financial Report 21st of May 2024 | PairCorr |
0.61 | DBVT | DBV Technologies Financial Report 2nd of May 2024 | PairCorr |
0.59 | KA | Kineta Inc Report 29th of March 2024 | PairCorr |
The ability to find closely correlated positions to Elanco Animal could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Elanco Animal when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Elanco Animal - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Elanco Animal Health to buy it.
The correlation of Elanco Animal is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Elanco Animal moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Elanco Animal Health moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Elanco Animal can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Elanco Animal Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Elanco Animal Health information on this page should be used as a complementary analysis to other Elanco Animal's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Complementary Tools for Elanco Stock analysis
When running Elanco Animal's price analysis, check to measure Elanco Animal's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elanco Animal is operating at the current time. Most of Elanco Animal's value examination focuses on studying past and present price action to predict the probability of Elanco Animal's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elanco Animal's price. Additionally, you may evaluate how the addition of Elanco Animal to your portfolios can decrease your overall portfolio volatility.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
CEOs Directory Screen CEOs from public companies around the world | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |
Is Elanco Animal's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Elanco Animal. If investors know Elanco will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Elanco Animal listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.097 | Earnings Share (2.50) | Revenue Per Share 8.972 | Quarterly Revenue Growth 0.051 | Return On Assets 0.0139 |
The market value of Elanco Animal Health is measured differently than its book value, which is the value of Elanco that is recorded on the company's balance sheet. Investors also form their own opinion of Elanco Animal's value that differs from its market value or its book value, called intrinsic value, which is Elanco Animal's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Elanco Animal's market value can be influenced by many factors that don't directly affect Elanco Animal's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Elanco Animal's value and its price as these two are different measures arrived at by different means. Investors typically determine if Elanco Animal is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Elanco Animal's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.